(PREventive Invasive Strategy for Obstructive Coronary Artery Disease With Vulnerable Plaque Eval… (NCT07569692) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
(PREventive Invasive Strategy for Obstructive Coronary Artery Disease With Vulnerable Plaque Evaluated by CoroNary Computed Tomography Angiography)-2
South Korea2,500 participantsStarted 2026-07-30
Plain-language summary
The PREVENT-2 trial is to determine whether an initial invasive strategy-consisting of early coronary angiography (CAG) with intent for preventive percutaneous coronary intervention (PCI) in addition to optimal medical therapy (OMT)-reduces the incidence of the primary composite outcome of cardiac death, target-vessel myocardial infarction (MI), unplanned urgent revascularization, or hospitalization for unstable or progressive angina at 3 years, compared with an initial conservative strategy of optimal medical therapy (OMT) alone, in patients with high-risk vulnerable plaque identified by coronary computed tomography angiography (CCTA).
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Patients aged ≥18 years
✓. Patients with suspected coronary artery disease (CAD) (e.g., chest pain syndrome or equivalent symptoms) who are evaluated with coronary computed tomography angiography (CCTA)
✕. Significant left main coronary artery disease (≥50% diameter stenosis)
✕. Coronary anatomy unsuitable for either percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)
✕. Left ventricular ejection fraction (LVEF) \<35%
✕. New York Heart Association (NYHA) class III or IV heart failure at entry or hospitalization for exacerbation of chronic heart failure within the previous 6 months
What they're measuring
1
The event rate of Composite of death from cardiac causes, target-vessel myocardial infarction, unplanned urgent revascularization, or hospitalization for unstable or progressive angina at 3 years after randomization.
Timeframe: 3 years
Trial details
NCT IDNCT07569692
SponsorSeung-Jung Park
Sponsor typeOTHER
Study typeINTERVENTIONAL
Primary completion2031-07-30
Contact for this trial
Duk-woo Park Professor in Department of Cardiology, Asan Medical Center, MD, PhD